A bubble in the biotech sector?

Growth-starved investors have piled into the Nasdaq in recent years, swelling the exchange's biotech index.

US biotechnology stocks have hit turbulence. The Nasdaq Biotechnology index has slid by 10% from its July peak. Since the March 2009 low, it has risen almost sevenfold, compared to a fourfold increase in the Nasdaq Composite index. In recent years, "growth-starved investors" have piled into the sector, happily paying top dollar for impressive sales growth, says Charley Grant in The Wall Street Journal.

In the second quarter, for instance, the top five biotechs by market value managed to grow combined sales by a total of 31% year-on-year. The overall stockmarket, as measured by the S&P 500, grew sales by just under 2%.

So as far as the bulls are concerned, high valuations are fully justified. But, as Ben Levisohn points out on barrons.com, "there comes a point when just rewards tip over into excess". Frothy flotations are one worry. "There has been an explosion of low-quality" initial public offerings, says Matarin Capital's Ralph Coutant. "It feels quite bubbly."

Furthermore, the Nasdaq Biotechnology index is on a price/earnings ratio of 85, compared to around 30 for the Nasdaq Composite (thisfigure peaked at almost 200 in 2000).The biotech sector is also on an eye-watering price-to-sales ratio of almost ten.

Not everyone is rattled. Star fund manger Neil Woodford has been "outspoken about his confidence in biotech stocks", say Julia Faurschou and Madison Marriage in the FT. But with signs of growth slowing at the bigger biotechs, making valuations harder to justify, fears of a correction seem likely to spread.

Recommended

Five online retail stocks to diversify your portfolio with
Share tips

Five online retail stocks to diversify your portfolio with

Professional investor Tancredi Cordero, founder and CEO of Kuros Associates, selects five of his favourite online retail stocks to buy now.
18 Jan 2021
Why investment forecasting is futile
Investment gurus

Why investment forecasting is futile

Every year events prove that forecasting is futile and 2020 was no exception, says Bill Miller, chairman and chief investment officer of Miller Value …
18 Jan 2021
Why investors should beware of India’s surging stockmarket
Emerging markets

Why investors should beware of India’s surging stockmarket

The BSE Sensex benchmark index has soared by 90% since March, largely driven by foreign investors. But India's bull market is very vulnerable.
15 Jan 2021
US stocks are obviously in a bubble. But is it a rational bubble?
US stockmarkets

US stocks are obviously in a bubble. But is it a rational bubble?

Everyone wants to know if the US stockmarket is in a bubble. But that is the wrong question, says Merryn Somerset Webb. Of course it’s a bubble. The r…
14 Jan 2021

Most Popular

Why we won’t see a house-price crash in 2021
House prices

Why we won’t see a house-price crash in 2021

Lockdown sent house prices berserk as cooped up home-workers fled for bigger properties in the country. And while they won’t rise quite as much this y…
18 Jan 2021
Prepare for the end of the epic bubble in US stocks
US stockmarkets

Prepare for the end of the epic bubble in US stocks

US stocks are as expensive as they’ve ever been. How can you prepare your portfolio for a bubble bursting?
18 Jan 2021
It's not just the UK – we're seeing pandemic housing booms across the globe
Property

It's not just the UK – we're seeing pandemic housing booms across the globe

Soaring house prices aren’t just a UK thing, they’re a worldwide phenomenon. And it’s no coincidence – the underlying cause is much the same. John Ste…
18 Jan 2021